These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 23324399)

  • 1. Relevance of a pre-existing measles immunity prior immunization with a recombinant measles virus vector.
    Knuchel MC; Marty RR; Morin TN; Ilter O; Zuniga A; Naim HY
    Hum Vaccin Immunother; 2013 Mar; 9(3):599-606. PubMed ID: 23324399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Priming T-cell responses with recombinant measles vaccine vector in a heterologous prime-boost setting in non-human primates.
    Bolton DL; Santra S; Swett-Tapia C; Custers J; Song K; Balachandran H; Mach L; Naim H; Kozlowski PA; Lifton M; Goudsmit J; Letvin N; Roederer M; Radošević K
    Vaccine; 2012 Sep; 30(41):5991-8. PubMed ID: 22732429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An immune competent mouse model for the characterization of recombinant measles vaccines.
    Marty RR; Knuchel MC; Morin TN; Naim HY
    Hum Vaccin Immunother; 2015; 11(1):83-90. PubMed ID: 25483519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Broadly neutralizing immune responses against hepatitis C virus induced by vectored measles viruses and a recombinant envelope protein booster.
    Reyes-del Valle J; de la Fuente C; Turner MA; Springfeld C; Apte-Sengupta S; Frenzke ME; Forest A; Whidby J; Marcotrigiano J; Rice CM; Cattaneo R
    J Virol; 2012 Nov; 86(21):11558-66. PubMed ID: 22896607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant measles viruses expressing single or multiple antigens of human immunodeficiency virus (HIV-1) induce cellular and humoral immune responses.
    Liniger M; Zuniga A; Morin TN; Combardiere B; Marty R; Wiegand M; Ilter O; Knuchel M; Naim HY
    Vaccine; 2009 May; 27(25-26):3299-305. PubMed ID: 19200842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform.
    Malczyk AH; Kupke A; Prüfer S; Scheuplein VA; Hutzler S; Kreuz D; Beissert T; Bauer S; Hubich-Rau S; Tondera C; Eldin HS; Schmidt J; Vergara-Alert J; Süzer Y; Seifried J; Hanschmann KM; Kalinke U; Herold S; Sahin U; Cichutek K; Waibler Z; Eickmann M; Becker S; Mühlebach MD
    J Virol; 2015 Nov; 89(22):11654-67. PubMed ID: 26355094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The successful induction of T-cell and antibody responses by a recombinant measles virus-vectored tetravalent dengue vaccine provides partial protection against dengue-2 infection.
    Hu HM; Chen HW; Hsiao YJ; Wu SH; Chung HH; Hsieh CH; Chong P; Leng CH; Pan CH
    Hum Vaccin Immunother; 2016 Jul; 12(7):1678-89. PubMed ID: 26901482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Control of SIV infection and subsequent induction of pandemic H1N1 immunity in rhesus macaques using an Ad5 [E1-, E2b-] vector platform.
    Gabitzsch ES; Balint-Junior JP; Xu Y; Balcaitis S; Sanders-Beer B; Karl J; Weinhold KJ; Paessler S; Jones FR
    Vaccine; 2012 Nov; 30(50):7265-70. PubMed ID: 23041546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses.
    Liniger M; Zuniga A; Tamin A; Azzouz-Morin TN; Knuchel M; Marty RR; Wiegand M; Weibel S; Kelvin D; Rota PA; Naim HY
    Vaccine; 2008 Apr; 26(17):2164-74. PubMed ID: 18346823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of attenuated measles virus engineered to express Helicobacter pylori neutrophil-activating protein.
    Iankov ID; Haralambieva IH; Galanis E
    Vaccine; 2011 Feb; 29(8):1710-20. PubMed ID: 21182995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intranasal immunization with the recombinant measles virus encoding the spike protein of SARS-CoV-2 confers protective immunity against COVID-19 in hamsters.
    Park SI; Park S; Lee K; Kwak HW; Kim YK; Park HJ; Bang YJ; Kim JY; Kim D; Seo KW; Lee SJ; Kim H; Kim Y; Kim DH; Park HJ; Jung SY; Ga E; Hwang J; Na W; Hong SH; Lee SM; Nam JH
    Vaccine; 2024 Jan; 42(2):69-74. PubMed ID: 38097457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant measles virus incorporating heterologous viral membrane proteins for use as vaccines.
    Swett-Tapia C; Bogaert L; de Jong P; van Hoek V; Schouten T; Damen I; Spek D; Wanningen P; Radošević K; Widjojoatmodjo MN; Zahn R; Custers J; Roy S
    J Gen Virol; 2016 Sep; 97(9):2117-2128. PubMed ID: 27311834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful mucosal immunization of cotton rats in the presence of measles virus-specific antibodies depends on degree of attenuation of vaccine vector and virus dose.
    Schlereth B; Buonocore L; Tietz A; Meulen VT; Rose JK; Niewiesk S
    J Gen Virol; 2003 Aug; 84(Pt 8):2145-2151. PubMed ID: 12867646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of immune responses induced by intramuscular vaccination with DNA vaccines encoding measles virus hemagglutinin and/or fusion proteins.
    Song MK; Vindurampulle CJ; Capozzo AV; Ulmer J; Polo JM; Pasetti MF; Barry EM; Levine MM
    J Virol; 2005 Aug; 79(15):9854-61. PubMed ID: 16014946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful vaccine-induced seroconversion by single-dose immunization in the presence of measles virus-specific maternal antibodies.
    Schlereth B; Rose JK; Buonocore L; ter Meulen V; Niewiesk S
    J Virol; 2000 May; 74(10):4652-7. PubMed ID: 10775601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Both mucosal and systemic routes of immunization with the live, attenuated NYVAC/simian immunodeficiency virus SIV(gpe) recombinant vaccine result in gag-specific CD8(+) T-cell responses in mucosal tissues of macaques.
    Stevceva L; Alvarez X; Lackner AA; Tryniszewska E; Kelsall B; Nacsa J; Tartaglia J; Strober W; Franchini G
    J Virol; 2002 Nov; 76(22):11659-76. PubMed ID: 12388726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial.
    Reisinger EC; Tschismarov R; Beubler E; Wiedermann U; Firbas C; Loebermann M; Pfeiffer A; Muellner M; Tauber E; Ramsauer K
    Lancet; 2019 Dec; 392(10165):2718-2727. PubMed ID: 30409443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranasal Sendai viral vector vaccination is more immunogenic than intramuscular under pre-existing anti-vector antibodies.
    Moriya C; Horiba S; Kurihara K; Kamada T; Takahara Y; Inoue M; Iida A; Hara H; Shu T; Hasegawa M; Matano T
    Vaccine; 2011 Nov; 29(47):8557-63. PubMed ID: 21939708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strong antigen-specific T-cell immunity induced by a recombinant human TERT measles virus vaccine and amplified by a DNA/viral vector prime boost in IFNAR/CD46 mice.
    Pliquet E; Ruffie C; Escande M; Thalmensi J; Najburg V; Combredet C; Bestetti T; Julithe M; Liard C; Huet T; Wain-Hobson S; Tangy F; Langlade-Demoyen P
    Cancer Immunol Immunother; 2019 Apr; 68(4):533-544. PubMed ID: 30656384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of next-generation HPV vaccines in non-human primates: Measles-vectored HPV vaccine versus Pichia pastoris recombinant protein vaccine.
    Gupta G; Giannino V; Rishi N; Glueck R
    Vaccine; 2016 Sep; 34(39):4724-4731. PubMed ID: 27523740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.